SCHEMBL4909514

SCHEMBL4909514

N#Cc1c(Cl)nc(NC2CC2)nc1-c1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 4/20 0.50
ADORA2B P29275 2/20 0.50
ADORA2A P29274 2/20 0.49
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ACHE P22303 3/20 0.42
MAPT P10636 1/20 0.39
GBA1 P04062 1/20 0.37
CTSV O60911 1/20 0.36
PLAT P00750 1/20 0.36
CTSL P07711 1/20 0.36
CTSH P09668 1/20 0.36
CTSS P25774 1/20 0.36
CASP14 P31944 1/20 0.36
CTSK P43235 1/20 0.36
CASP6 P55212 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907005 0.88 ACHE (0.41) ADORA1ADORA2BADORA2AALDH1A1KDM4E
SCHEMBL4906676 0.86 ACHE (0.43) ADORA1ADORA2BADORA2AACHECTSV
SCHEMBL4898493 0.85 ADORA1 (0.50) ADORA1ADORA2BADORA2AALDH1A1KDM4E
SCHEMBL4907027 0.82 ADORA2A (0.47) ADORA1ADORA2AALDH1A1KDM4EHPGD
SCHEMBL4898439 0.80 KDM1A (0.52) ADORA1ADORA2BADORA2AACHECTSV
SCHEMBL4904086 0.78 ACHE (0.43) ALDH1A1HPGDACHEMAPTCTSS
SCHEMBL4906255 0.77 ADORA1 (0.47) ADORA1ADORA2BADORA2AALDH1A1HPGD
SCHEMBL4899212 0.77 KDM1A (0.47) ADORA1ADORA2AALDH1A1KDM4EHPGD
SCHEMBL4907067 0.77 PDE4A (0.44) KDM4EACHECTSVPLATCTSL
SCHEMBL4900982 0.76 ALDH1A1 (0.48) ADORA1ADORA2BADORA2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ADORA1 529/4885ADORA2B 953/4885ADORA2A 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.